Navigation Links
OncoGenex Reports First Quarter Financial Results
Date:5/6/2010

cancer ("NSCLC") are on track to initiate in the third quarter of 2010, the second half of 2010 and early 2011, respectively."

Recent Business Highlights:

OGX-011

    -   The European Medicines Agency confirmed that they are in overall
        agreement with our Phase III development plan for OGX-011 in patients
        with CRPC.
    -   Two peer-reviewed manuscripts were published that further explain the
        biological function of clusterin, its role in promoting tumor
        resistance to cancer treatment, and the role of an inhibitor of
        clusterin such as OGX-011, to enhance the effectiveness of cancer
        therapies. One of the co-authors to these manuscripts, Dr. Martin
        Gleave, is also the Company's Chief Scientific Advisor.

OGX-427

    -   Grant funding was secured for a randomized, investigator-sponsored
        Phase II trial of OGX-427 when administered as a monotherapy to
        patients with CRPC.
    -   Two peer-reviewed manuscripts were published that provide further
        insight into the mechanism of action of heat shock protein 27
        (Hsp27). OGX-427 is designed to reduce levels of Hsp27.
    -   Final results from a Phase 1 study involving OGX-427 will be
        presented as part of the Scientific Program in a General Poster
        Session with discussion at the ASCO 2010 Annual Meeting. These final
        data, including results combining OGX-427 with docetaxel, will update
        preliminary data that was featured in an oral presentation at the
        ASCO 2009 meeting.

Corporate Highlights

    -   Dr. Jack Goldstein and Ms. H. Stewart Parker were appointed to the
        board of directors. Dr. Goldstein joins the board as chairman. In
        addition, Dr. Martin Mattingly has agreed to stand for election at
        the Company's upcoming
'/>"/>
SOURCE OncoGenex Pharmaceuticals, Inc.
Copyright©2010 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9

Related biology technology :

1. OncoGenex Pharmaceuticals to Webcast Discussion of Financial Results for Fourth Quarter and Fiscal Year 2009
2. OncoGenex Pharmaceuticals to Present at RBC Capital Markets Healthcare Conference
3. Teva Expands Innovative Pipeline with License Agreement to Develop and Commercialize OncoGenex Late Stage Innovative Treatment for Multiple Oncology Indications
4. OncoGenex Pharmaceuticals to Host Investor Conference Call at 8:30 a.m. ET, December 21, 2009
5. OncoGenex Reports Third Quarter 2009 Financial Results
6. OncoGenex Pharmaceuticals to Release Third Quarter 2009 Financial Results
7. OncoGenex Pharmaceuticals CEO Named Canadas Pacific Ernst & Youngs Entrepreneur Of The Year(R) in the Health Sciences Category
8. OncoGenex Pharmaceuticals to Webcast Presentations at September Investor Conferences
9. OncoGenex Pharmaceuticals Announces Issuance of Key Patent for OGX-011
10. OncoGenex Reports Second Quarter 2009 Financial Results
11. OncoGenex Pharmaceuticals to Release Second Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/1/2015)... 1, 2015   Decision Resources Group ... of Otezla are its oral administration, alternative mechanism ... by surveyed rheumatologists. Otezla was the first oral ... of active psoriatic arthritis in the ... care includes conventional oral treatments including disease-modifying antirheumatic ...
(Date:7/1/2015)... , July 1, 2015 Isagenix International, ... has earned three Gold, three Silver, and three Bronze ... gala held in Chicago this ... the premier business awards program in the U.S. ... our company,s strength in developing leaders, cultivating talent, creating ...
(Date:7/1/2015)... YORK , July 1, 2015  UCB, ... G ), a global leader in designing, transforming, ... Aecus Innovation Award in recognition of their close ... efficiencies in UCB,s global business services (GBS) finance ... service providers and clients that work together effectively ...
(Date:6/30/2015)... , June 30, 2015  NASA astronaut Kjell ... next month on his first mission to the International ... from 8 to 9 a.m. EDT Tuesday, July 7. ... in Star City, Russia . The interviews ... NASA Television highlighting his mission training. To schedule ...
Breaking Biology Technology:Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 2Surveyed Rheumatologists Report That Otezla's Oral Administration is its Single Greatest Advantage Over Currently Available Treatment Options 3Isagenix Earns Nine American Business Awards 2Isagenix Earns Nine American Business Awards 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 2UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 3UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 4UCB and Genpact Receive Aecus Innovation Award for Success in Global Business Services 5NASA Astronaut Preps for First Space Station Mission, Available for Media Interviews 2
... France, March 3 NicOx S.A.,(Euronext Paris: COX) ... studies in the United States, which will assess ... ibuprofen and naproxen,using the Ambulatory Blood Pressure Monitoring ... in duration, will together recruit a,total of around ...
... March 3 BioWa, Inc. announced today,that ... Genentech, Inc. providing,Genentech additional access to BioWa,s ... select antibodies for potential therapeutic,applications that require ... is pleased to extend this license with ...
... RALEIGH, N.C., Feb. 29 For the first ... that,microscopic "two-faced" spheres whose halves are physically or ... like stealthy,submarines when an alternating electrical field is ... describing the research, published in the Feb. 8, ...
Cached Biology Technology:NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 2NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 3NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 4NicOx Initiates Two Large ABPM Studies for Naproxcinod in Hypertensive Patients with Osteoarthritis 5BioWa Announces Expansion of License Agreement with Genentech for BioWa's POTELLIGENT(R) Technology 2'Two-Faced' Particles Act Like Tiny Submarines 2'Two-Faced' Particles Act Like Tiny Submarines 3
(Date:6/24/2015)... NEW YORK , June 24, 2015 ... favorable rate. The major drivers for the market include ... increasing number of new drug launches. Over the years, ... has increased. Between 2001 and 2010, the FDA approved ... addition, according to WIPO, Europe ...
(Date:6/24/2015)... June 22, 2015 ... addition of the "Huawei Ascend Mate 7 ... to their offering. Huawei,s technological choice ... opposite direction than Apple,s and Samsung,s one. The ... developed by Fingerprint Cards, a main actor in ...
(Date:6/23/2015)... 22, 2015 Research ... of the "Body-Worn Temperature Sensors Market - ... Forecast 2014 - 2020" report to their ... of the global body-worn temperature sensors market. The ... on the basis of types, care setting, patient ...
Breaking Biology News(10 mins):Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 2Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 3Biological Safety Testing Market by Application, Product, & Test - Global Forecast to 2019 4Huawei Ascend Mate 7 Fingerprint Sensor - Reverse Costing Analysis 2Body-Worn Temperature Sensors Market - Global Industry Analysis 2
... are known to count the days until spring. Now, scientists ... Addressing scientists here today (Aug. 9) at a meeting of ... Richard Amasino described studies that have begun to peel back ... to bloom at the optimal time of year. , "Flowering ...
... protrusions called axons that sniff their way through a ... them to their target. , While several recent ... incorrect targets in the limb, scientists at the Salk ... as FGF, that actively lures growing axons closer to ...
... evidence suggesting an alternative form of natural vitamin E can ... humans at levels determined to protect against stroke and other ... forms. The primary vitamin E on drugstore shelves is called ... surfacing as a potent neuroprotective agent in repeated Ohio State ...
Cached Biology News:Genetic snooze button governs timing of spring flowers 2Genetic snooze button governs timing of spring flowers 3New roles for growth factors: Enticing nerve cells to muscles 2New roles for growth factors: Enticing nerve cells to muscles 3Natural vitamin E tocotrienol reaches blood at protective levels 2Natural vitamin E tocotrienol reaches blood at protective levels 3
...
Mouse Anti-Gemin2...
Human Presenilin-2 NTF Affinity Purified Polyclonal Ab...
... Cryo/CryoPlus Inventory Racks for ... available with cardboard or stainless ... or 5ml cryo vials. ... racks available. Platform risers ...
Biology Products: